Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:FDMT NASDAQ:IMMX NASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.06$1.28$0.88▼$1.71$122.16M0.72342,752 shs257,402 shsFDMT4D Molecular Therapeutics$9.66$9.42$3.68▼$12.34$504.99M2.75811,859 shs892,221 shsIMMXImmix Biopharma$8.72$9.20$1.94▼$11.61$474.47M0.11.74 million shs7.42 million shsNGNENeurogene$31.53$27.73$14.65▼$37.27$498.23M1.69148,094 shs308,929 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%-0.93%-15.87%+14.47%-19.70%FDMT4D Molecular Therapeutics+2.55%+9.28%+15.00%+12.20%+136.19%IMMXImmix Biopharma-4.49%+7.65%-1.91%-4.28%+264.85%NGNENeurogene+2.40%+8.72%+17.30%+65.51%+72.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.06$1.28$0.88▼$1.71$122.16M0.72342,752 shs257,402 shsFDMT4D Molecular Therapeutics$9.66$9.42$3.68▼$12.34$504.99M2.75811,859 shs892,221 shsIMMXImmix Biopharma$8.72$9.20$1.94▼$11.61$474.47M0.11.74 million shs7.42 million shsNGNENeurogene$31.53$27.73$14.65▼$37.27$498.23M1.69148,094 shs308,929 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%-0.93%-15.87%+14.47%-19.70%FDMT4D Molecular Therapeutics+2.55%+9.28%+15.00%+12.20%+136.19%IMMXImmix Biopharma-4.49%+7.65%-1.91%-4.28%+264.85%NGNENeurogene+2.40%+8.72%+17.30%+65.51%+72.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50701.89% UpsideFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88209.27% UpsideIMMXImmix Biopharma 2.67Moderate Buy$20.67137.00% UpsideNGNENeurogene 3.00Buy$84.83169.06% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, FDMT, NGNE, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/9/2026NGNENeurogene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.006/3/2026NGNENeurogene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.006/3/2026NGNENeurogene Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.006/3/2026NGNENeurogene Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$70.005/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$69.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AFDMT4D Molecular Therapeutics$85.21M5.93N/AN/A$8.85 per share1.09IMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ANGNENeurogene$930K535.67N/AN/A$17.10 per share1.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)FDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-36.83%-32.55%8/10/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)NGNENeurogene-$90.35M-$4.55N/AN/AN/AN/A-37.88%-34.70%8/10/2026 (Estimated)Latest CRDL, FDMT, NGNE, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026NGNENeurogene-$1.2963-$1.39-$0.0938-$1.39N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/24/2026Q4 2025NGNENeurogene-$1.20-$1.12+$0.08-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39FDMT4D Molecular TherapeuticsN/A9.349.34IMMXImmix BiopharmaN/A8.758.75NGNENeurogeneN/A13.0813.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%FDMT4D Molecular Therapeutics99.27%IMMXImmix Biopharma11.26%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%FDMT4D Molecular Therapeutics7.90%IMMXImmix Biopharma30.30%NGNENeurogene11.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableFDMT4D Molecular Therapeutics12052.28 million48.15 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableNGNENeurogene9015.80 million13.96 millionOptionableCRDL, FDMT, NGNE, and IMMX HeadlinesRecent News About These CompaniesNeurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett SyndromeJune 8, 2026 | finance.yahoo.comNeurogene Announces Successful Completion of Dosing in Emboldenâ„¢ Registrational Trial of NGN-401 for Rett SyndromeJune 8, 2026 | businesswire.comNeurogene Stockholders Vote on Directors and Executive PayJune 4, 2026 | tipranks.comHC Wainwright Has Pessimistic View of Neurogene Q2 EarningsMay 20, 2026 | marketbeat.comNeurogene Reports First Quarter 2026 Financial Results and Highlights Recent UpdatesMay 12, 2026 | businesswire.comInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 9,600 Shares of StockMay 9, 2026 | insidertrades.comWe Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business GrowthMay 5, 2026 | finance.yahoo.comNeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyApril 28, 2026 | finance.yahoo.comNeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of DirectorsApril 20, 2026 | businesswire.comNeurogene Inc.April 8, 2026 | edition.cnn.comNeurogene (NGNE) price target increased by 37.29% to 82.62March 27, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)March 26, 2026 | theglobeandmail.comNeurogene: Q4 Earnings SnapshotMarch 24, 2026 | finance.yahoo.comNeurogene Reports Full Year 2025 Financial Results and Highlights Recent UpdatesMarch 24, 2026 | businesswire.comNeurogene (NASDAQ:NGNE) CFO Sells $84,176.45 in StockMarch 18, 2026 | insidertrades.comNeurogene to Participate in Stifel 2026 Virtual CNS ForumMarch 11, 2026 | businesswire.comNeurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain CautiousFebruary 27, 2026 | seekingalpha.comNeurogene stock surges 30% on FDA breakthrough therapy statusFebruary 26, 2026 | uk.investing.comNeurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett SyndromeFebruary 26, 2026 | pharmiweb.comPNeurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett SyndromeFebruary 26, 2026 | businesswire.comNeurogene Insider Trading Activity | NASDAQ:NGNE | BenzingaJanuary 31, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, FDMT, NGNE, and IMMX Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.06 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.47%) As of 06/18/2026 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.4D Molecular Therapeutics NASDAQ:FDMT$9.66 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$9.65 -0.01 (-0.05%) As of 06/18/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Immix Biopharma NASDAQ:IMMX$8.72 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.78 +0.05 (+0.63%) As of 06/18/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Neurogene NASDAQ:NGNE$31.53 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$31.50 -0.03 (-0.10%) As of 06/18/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
